More recently, to evaluate whether polygenic risk scores (PRS) could aid in predicting the response to standard cluster headache treatments (oxygen, triptans, and verapamil), Petersen et al. (2023) conducted a study on 508 patients by genotyping several SNPs in CYP3A4 and applying PRS derived from a meta-analysis of the latest two cluster headache GWAS studies (Harder et al., 2021; O’Connor et al., 2021). Here, CYP3A4 is linked to Cluster headache.